Seizert Capital Partners LLC Has $12.05 Million Stake in Exelixis, Inc. $EXEL

Seizert Capital Partners LLC lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 15.9% in the third quarter, Holdings Channel reports. The firm owned 291,862 shares of the biotechnology company’s stock after selling 55,227 shares during the period. Seizert Capital Partners LLC’s holdings in Exelixis were worth $12,054,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after buying an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after acquiring an additional 68,133 shares during the period. Focus Partners Wealth grew its position in shares of Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after purchasing an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in shares of Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares during the period. Finally, Sivia Capital Partners LLC lifted its position in shares of Exelixis by 23.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after purchasing an additional 2,764 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In other Exelixis news, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the transaction, the director directly owned 1,189,228 shares of the company’s stock, valued at approximately $51,790,879.40. This trade represents a 7.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 34,187 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $41.88, for a total transaction of $1,431,751.56. The SEC filing for this sale provides additional information. Insiders have sold 245,235 shares of company stock valued at $10,490,600 in the last ninety days. Corporate insiders own 2.85% of the company’s stock.

Exelixis Trading Down 0.5%

EXEL opened at $43.74 on Tuesday. The company has a fifty day moving average price of $43.58 and a two-hundred day moving average price of $41.09. Exelixis, Inc. has a 1-year low of $31.90 and a 1-year high of $49.62. The company has a market cap of $11.73 billion, a P/E ratio of 18.47, a price-to-earnings-growth ratio of 0.79 and a beta of 0.40.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million during the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.47 earnings per share. On average, research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several research reports. Stifel Nicolaus set a $43.00 price objective on Exelixis in a research report on Wednesday, November 5th. TD Cowen upped their price target on shares of Exelixis from $44.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Morgan Stanley reiterated an “equal weight” rating and set a $48.00 target price (up from $45.00) on shares of Exelixis in a research report on Thursday, January 8th. Bank of America lowered shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price objective on the stock. in a research note on Monday, January 5th. Finally, Wells Fargo & Company dropped their price target on Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $45.95.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.